Neuroimaging biomarkers in Alzheimer's disease and other dementias

Ageing Research Reviews

Volumn 30, Issue , 2016, Pages 4-16

  Villemagne, Victor L ^a,b,c,d   Chételat, Gaël ^c,d,e,f,g  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d INSERM   (France)

^e UNIVERSITÉ DE CAEN   (France)

^f PSL RESEARCH UNIVERSITY   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease; A ; Brain imaging; Neurodegenerative disorders; Positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COGNITION; FRONTOTEMPORAL DEMENTIA; HUMAN; LEWY BODY; MOLECULAR IMAGING; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRION DISEASE; REVIEW; VASCULAR AMYLOIDOSIS; ANIMAL; DEMENTIA; DIAGNOSTIC IMAGING; METABOLISM; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOMARKERS; DEMENTIA; HUMANS; NEUROIMAGING;

EID: 84991974725     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2016.01.004     Document Type: Review

References (231)

1. Aizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J.C., Mathis, C.A., Tsopelas, N.D., Ziolko, S.K., James, J.A., Snitz, B.E., Houck, P.R., Bi, W., Cohen, A.D., Lopresti, B.J., Dekosky, S.T., Halligan, E.M., Klunk, W.E., Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65 (2008), 1509–1517.
2. Albert, M.S., Dekosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, P.J., Carrillo, M.C., Thies, B., Phelps, C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7 (2011), 270–279.
3. Altmann, A., Ng, B., Landau, S.M., Jagust, W.J., Greicius, M.D., Alzheimer's Disease Neuroimaging, I., Alzheimer's Disease Neuroimaging, Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain 138:Pt 12 (2015), 3734–3746.
4. Armstrong, R.A., Cairns, N.J., Lantos, P.L., Beta-amyloid deposition in the temporal lobe of patients with dementia with Lewy bodies: comparison with non-demented cases and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11 (2000), 187–192.
5. Barthel, H., Gertz, H.J., Dresel, S., Peters, O., Bartenstein, P., Buerger, K., Hiemeyer, F., Wittemer-Rump, S.M., Seibyl, J., Reininger, C., Sabri, O., Cerebral amyloid-beta PET with florbetaben ((18)F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 10 (2011), 424–435.
6. Bateman, R.J., Munsell, L.Y., Morris, J.C., Swarm, R., Yarasheski, K.E., Holtzman, D.M., Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12 (2006), 856–861.
7. Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M., Holtzman, D.M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P.S., Ghetti, B., Klunk, W.E., McDade, E., Martins, R.N., Masters, C.L., Mayeux, R., Ringman, J.M., Rossor, M.N., Schofield, P.R., Sperling, R.A., Salloway, S., Morris, J.C., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367 (2012), 795–804.
8. Beach, T.G., Monsell, S.E., Phillips, L.E., Kukull, W., Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J. Neuropathol. Exp. Neurol. 71 (2012), 266–273.
9. Blennow, K., Zetterberg, H., Minthon, L., Lannfelt, L., Strid, S., Annas, P., Basun, H., Andreasen, N., Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci. Lett. 419 (2007), 18–22.
10. Bourgeat, P., Chetelat, G., Villemagne, V.L., Fripp, J., Raniga, P., Pike, K., Acosta, O., Szoeke, C., Ourselin, S., Ames, D., Ellis, K.A., Martins, R.N., Masters, C.L., Rowe, C.C., Salvado, O., Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 74 (2010), 121–127.
11. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82 (1991), 239–259.
12. Braak, H., Braak, E., Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18 (1997), 351–357.
13. Braak, H., Del Tredici, K., The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 121 (2011), 171–181.
14. Buckner, R.L., Andrews-Hanna, J.R., Schacter, D.L., The brain's default network: anatomy, function, and relevance to disease. Ann. N. Y. Acad. Sci. 1124 (2008), 1–38.
15. Buckner, R.L., Snyder, A.Z., Shannon, B.J., LaRossa, G., Sachs, R., Fotenos, A.F., Sheline, Y.I., Klunk, W.E., Mathis, C.A., Morris, J.C., Mintun, M.A., Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 25 (2005), 7709–7717.
16. Cairns, N.J., Bigio, E.H., Mackenzie, I.R., Neumann, M., Lee, V.M., Hatanpaa, K.J., White, C.L. 3rd, Schneider, J.A., Grinberg, L.T., Halliday, G., Duyckaerts, C., Lowe, J.S., Holm, I.E., Tolnay, M., Okamoto, K., Yokoo, H., Murayama, S., Woulfe, J., Munoz, D.G., Dickson, D.W., Ince, P.G., Trojanowski, J.Q., Mann, D.M., Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 114 (2007), 5–22.
17. Camus, V., Payoux, P., Barre, L., Desgranges, B., Voisin, T., Tauber, C., La Joie, R., Tafani, M., Hommet, C., Chetelat, G., Mondon, K., de La Sayette, V., Cottier, J.P., Beaufils, E., Ribeiro, M.J., Gissot, V., Vierron, E., Vercouillie, J., Vellas, B., Eustache, F., Guilloteau, D., Using PET with (18)F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur. J. Nucl. Med. Mol. Imaging 39:4 (2012), 621–631.
18. Cappai, R., White, A.R., Amyloid beta. Int. J. Biochem. Cell Biol. 31 (1999), 885–889.
19. Carter, S.F., Scholl, M., Almkvist, O., Wall, A., Engler, H., Langstrom, B., Nordberg, A., Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J. Nucl. Med. 53 (2012), 37–46.
20. Chetelat, G., Alzheimer disease: Abeta-independent processes-rethinking preclinical AD. Nat. Rev. Neurol. 9 (2013), 123–124.
21. Chetelat, G., Desgranges, B., de la Sayette, V., Viader, F., Berkouk, K., Landeau, B., Lalevee, C., Le Doze, F., Dupuy, B., Hannequin, D., Baron, J.C., Eustache, F., Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 126 (2003), 1955–1967.
22. Chetelat, G., Eustache, F., Viader, F., De La Sayette, V., Pelerin, A., Mezenge, F., Hannequin, D., Dupuy, B., Baron, J.C., Desgranges, B., FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 11 (2005), 14–25.
23. Chetelat, G., La Joie, R., Villain, N., Perrotin, A., de La Sayette, V., Eustache, F., Vandenberghe, R., Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. NeuroImage Clin. 2 (2013), 356–365.
24. Chetelat, G., Villemagne, V.L., Bourgeat, P., Pike, K.E., Jones, G., Ames, D., Ellis, K.A., Szoeke, C., Martins, R.N., O'Keefe, G.J., Salvado, O., Masters, C.L., Rowe, C.C., Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann. Neurol. 67 (2010), 317–324.
25. Chetelat, G., Villemagne, V.L., Pike, K.E., Baron, J.C., Bourgeat, P., Jones, G., Faux, N.G., Ellis, K.A., Salvado, O., Szoeke, C., Martins, R.N., Ames, D., Masters, C.L., Rowe, C.C., Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 133 (2010), 3349–3358.
26. Chetelat, G., Villemagne, V.L., Villain, N., Jones, G., Ellis, K.A., Ames, D., Martins, R.N., Masters, C.L., Rowe, C.C., Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 78 (2012), 477–484.
27. Clark, C.M., Davatzikos, C., Borthakur, A., Newberg, A., Leight, S., Lee, V.M., Trojanowski, J.Q., Biomarkers for early detection of Alzheimer pathology. Neurosignals 16 (2008), 11–18.
28. Coleman, R.E., Positron emission tomography diagnosis of Alzheimer's disease. Neuroimaging Clin. N. Am. 15 (2005), 837–846 x.
29. Cordonnier, C., Brain microbleeds. Pract. Neurol. 10 (2010), 94–100.
30. Cselenyi, Z., Jonhagen, M.E., Forsberg, A., Halldin, C., Julin, P., Schou, M., Johnstrom, P., Varnas, K., Svensson, S., Farde, L., Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J. Nucl. Med. 53 (2012), 415–424.
31. Cummings, J.L., Morstorf, T., Zhong, K., Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res. Ther., 6, 2014, 37.
32. Cummings, J.L., Vinters, H.V., Cole, G.M., Khachaturian, Z.S., Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51 (1998), S2–S17 discussion S65–S17.
33. Davies, L., Wolska, B., Hilbich, C., Multhaup, G., Martins, R., Simms, G., Beyreuther, K., Masters, C.L., A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38 (1988), 1688–1693.
34. de Leon, M.J., DeSanti, S., Zinkowski, R., Mehta, P.D., Pratico, D., Segal, S., Rusinek, H., Li, J., Tsui, W., Saint Louis, L.A., Clark, C.M., Tarshish, C., Li, Y., Lair, L., Javier, E., Rich, K., Lesbre, P., Mosconi, L., Reisberg, B., Sadowski, M., DeBernadis, J.F., Kerkman, D.J., Hampel, H., Wahlund, L.O., Davies, P., Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging 27 (2006), 394–401.
35. de Leon, M.J., Mosconi, L., Blennow, K., DeSanti, S., Zinkowski, R., Mehta, P.D., Pratico, D., Tsui, W., Saint Louis, L.A., Sobanska, L., Brys, M., Li, Y., Rich, K., Rinne, J., Rusinek, H., Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann. N. Y. Acad. Sci. 1097 (2007), 114–145.
36. DeKosky, S.T., Ikonomovic, M.D., Styren, S.D., Beckett, L., Wisniewski, S., Bennett, D.A., Cochran, E.J., Kordower, J.H., Mufson, E.J., Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 51 (2002), 145–155.
37. Delacourte, A., Sergeant, N., Wattez, A., Maurage, C.A., Lebert, F., Pasquier, F., David, J.P., Tau aggregation in the hippocampal formation: an ageing or a pathological process?. Exp. Gerontol. 37 (2002), 1291–1296.
38. Devanand, D.P., Jacobs, D.M., Tang, M.X., Del Castillo-Castaneda, C., Sano, M., Marder, K., Bell, K., Bylsma, F.W., Brandt, J., Albert, M., Stern, Y., The course of psychopathologic features in mild to moderate Alzheimer disease. Arch. Gen. Psychiatry 54 (1997), 257–263.
39. Dhollander, I., Nelissen, N., Van Laere, K., Peeters, D., Demaerel, P., Van Paesschen, W., Thijs, V., Vandenberghe, R., In vivo amyloid imaging in cortical superficial siderosis. J. Neurol. Neurosurg. Psychiatry 82 (2011), 469–471.
40. Dickerson, B.C., Bakkour, A., Salat, D.H., Feczko, E., Pacheco, J., Greve, D.N., Grodstein, F., Wright, C.I., Blacker, D., Rosas, H.D., Sperling, R.A., Atri, A., Growdon, J.H., Hyman, B.T., Morris, J.C., Fischl, B., Buckner, R.L., The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 19 (2009), 497–510.
41. Dierksen, G.A., Skehan, M.E., Khan, M.A., Jeng, J., Nandigam, R.N., Becker, J.A., Kumar, A., Neal, K.L., Betensky, R.A., Frosch, M.P., Rosand, J., Johnson, K.A., Viswanathan, A., Salat, D.H., Greenberg, S.M., Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann. Neurol. 68 (2010), 545–548.
42. Doody, R.S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R.G., Aisen, P.S., Steering, C., Siemers, E., Sethuraman, G., Mohs, R., Semagacestat Alzheimer's Disease Cooperative Study, G., A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 369:4 (2013), 341–350.
43. Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P.S., Siemers, E., Liu-Seifert, H., Mohs, R., Alzheimer's Disease Cooperative Study Steering, C., Solanezumab Study, G., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370:4 (2014), 311–321.
44. Doraiswamy, P.M., Sperling, R.A., Coleman, R.E., Johnson, K.A., Reiman, E.M., Davis, M.D., Grundman, M., Sabbagh, M.N., Sadowsky, C.H., Fleisher, A.S., Carpenter, A., Clark, C.M., Joshi, A.D., Mintun, M.A., Skovronsky, D.M., Pontecorvo, M.J., Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 79 (2012), 1636–1644.
45. Doraiswamy, P.M., Sperling, R.A., Johnson, K., Reiman, E.M., Wong, T.Z., Sabbagh, M.N., Sadowsky, C.H., Fleisher, A.S., Carpenter, A., Joshi, A.D., Lu, M., Grundman, M., Mintun, M.A., Skovronsky, D.M., Pontecorvo, M.J., Group, A.A.S., Group, A.A.S., Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study. Mol. Psychiatry 19 (2014), 1044–1051.
46. Drago, V., Babiloni, C., Bartres-Faz, D., Caroli, A., Bosch, B., Hensch, T., Didic, M., Klafki, H.W., Pievani, M., Jovicich, J., Venturi, L., Spitzer, P., Vecchio, F., Schoenknecht, P., Wiltfang, J., Redolfi, A., Forloni, G., Blin, O., Irving, E., Davis, C., Hardemark, H.G., Frisoni, G.B., Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. J. Alzheimers Dis. 26:Suppl. 3 (2011), 159–199.
47. Drzezga, A., Grimmer, T., Henriksen, G., Stangier, I., Perneczky, R., Diehl-Schmid, J., Mathis, C.A., Klunk, W.E., Price, J., DeKosky, S., Wester, H.J., Schwaiger, M., Kurz, A., Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 39 (2008), 619–633.
48. Drzezga, A., Grimmer, T., Riemenschneider, M., Lautenschlager, N., Siebner, H., Alexopoulus, P., Minoshima, S., Schwaiger, M., Kurz, A., Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J. Nucl. Med. 46 (2005), 1625–1632.
49. Drzezga, A., Lautenschlager, N., Siebner, H., Riemenschneider, M., Willoch, F., Minoshima, S., Schwaiger, M., Kurz, A., Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 30 (2003), 1104–1113.
50. Dubois, B., Feldman, H.H., Jacova, C., Cummings, J.L., Dekosky, S.T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N.C., Galasko, D., Gauthier, S., Hampel, H., Jicha, G.A., Meguro, K., O'Brien, J., Pasquier, F., Robert, P., Rossor, M., Salloway, S., Sarazin, M., de Souza, L.C., Stern, Y., Visser, P.J., Scheltens, P., Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9 (2010), 1118–1127.
51. Duyckaerts, C., Tau pathology in children and young adults: can you still be unconditionally baptist?. Acta Neuropathol. 121 (2011), 145–147.
52. Edison, P., Archer, H.A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F.E., Hammers, A., Tai, Y.F., Fox, N., Kennedy, A., Rossor, M., Brooks, D.J., Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis. 32 (2008), 412–419.
53. Edison, P., Rowe, C.C., Rinne, J.O., Ng, S., Ahmed, I., Kemppainen, N., Villemagne, V.L., O'Keefe, G., Nagren, K., Chaudhury, K.R., Masters, C.L., Brooks, D.J., Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J. Neurol. Neurosurg. Psychiatry 79 (2008), 1331–1338.
54. Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A., Ringheim, A., Langstrom, B., Nordberg, A., Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129 (2006), 2856–2866.
55. Engler, H., Santillo, A.F., Wang, S.X., Lindau, M., Savitcheva, I., Nordberg, A., Lannfelt, L., Langstrom, B., Kilander, L., In vivo amyloid imaging with PET in frontotemporal dementia. Eur. J. Nucl. Med. Mol. Imaging 35 (2008), 100–106.
56. Fagan, A.M., Mintun, M.A., Mach, R.H., Lee, S.Y., Dence, C.S., Shah, A.R., Larossa, G.N., Spinner, M.L., Klunk, W.E., Mathis, C.A., Dekosky, S.T., Morris, J.C., Holtzman, D.M., Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Ann. Neurol. 59 (2006), 512–519.
57. Fagan, A.M., Mintun, M.A., Shah, A.R., Aldea, P., Roe, C.M., Mach, R.H., Marcus, D., Morris, J.C., Holtzman, D.M., Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol. Med. 1 (2009), 371–380.
58. Fagan, A.M., Roe, C.M., Xiong, C., Mintun, M.A., Morris, J.C., Holtzman, D.M., Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64 (2007), 343–349.
59. Feldman, H.H., Maia, L.F., Mackenzie, I.R., Forster, B.B., Martzke, J., Woolfenden, A., Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer disease. Stroke 39 (2008), 2894–2897.
60. Fleisher, A.S., Chen, K., Liu, X., Roontiva, A., Thiyyagura, P., Ayutyanont, N., Joshi, A.D., Clark, C.M., Mintun, M.A., Pontecorvo, M.J., Doraiswamy, P.M., Johnson, K.A., Skovronsky, D.M., Reiman, E.M., Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch. Neurol. 68 (2011), 1404–1411.
61. Forman, M.S., Mufson, E.J., Leurgans, S., Pratico, D., Joyce, S., Leight, S., Lee, V.M., Trojanowski, J.Q., Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology 68 (2007), 757–763.
62. Forsberg, A., Almkvist, O., Engler, H., Wall, A., Langstrom, B., Nordberg, A., High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr. Alzheimer Res. 7 (2010), 56–66.
63. Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A., Langstrom, B., Nordberg, A., PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29 (2008), 1456–1465.
64. Fox, N., When, where, and how does Alzheimer's disease start?. Lancet Neurol. 11 (2012), 1017–1018.
65. Frisoni, G.B., Fox, N.C., Jack, C.R. Jr., Scheltens, P., Thompson, P.M., The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 6 (2010), 67–77.
66. Furst, A.J., Rabinovici, G.D., Rostomian, A.H., Steed, T., Alkalay, A., Racine, C., Miller, B.L., Jagust, W.J., Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol. Aging 33:2 (2010), 215–225.
67. Gomperts, S.N., Rentz, D.M., Moran, E., Becker, J.A., Locascio, J.J., Klunk, W.E., Mathis, C.A., Elmaleh, D.R., Shoup, T., Fischman, A.J., Hyman, B.T., Growdon, J.H., Johnson, K.A., Imaging amyloid deposition in Lewy body diseases. Neurology 71 (2008), 903–910.
68. Grimmer, T., Riemenschneider, M., Forstl, H., Henriksen, G., Klunk, W.E., Mathis, C.A., Shiga, T., Wester, H.J., Kurz, A., Drzezga, A., Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol. Psychiatry 65 (2009), 927–934.
69. Gurol, M.E., Dierksen, G., Betensky, R., Gidicsin, C., Halpin, A., Becker, A., Carmasin, J., Ayres, A., Schwab, K., Viswanathan, A., Salat, D., Rosand, J., Johnson, K.A., Greenberg, S.M., Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology 79 (2012), 320–326.
70. Hampel, H., Blennow, K., Shaw, L.M., Hoessler, Y.C., Zetterberg, H., Trojanowski, J.Q., Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 45 (2010), 30–40.
71. Hansson, O., Zetterberg, H., Buchhave, P., Andreasson, U., Londos, E., Minthon, L., Blennow, K., Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 23 (2007), 316–320.
72. Hardy, J., An ‘anatomical cascade hypothesis’ for Alzheimer's disease. Trends Neurosci. 15 (1992), 200–201.
73. Hardy, J., Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20 (1997), 154–159.
74. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
75. Hill, A.F., Joiner, S., Wadsworth, J.D., Sidle, K.C., Bell, J.E., Budka, H., Ironside, J.W., Collinge, J., Molecular classification of sporadic Creutzfeldt–Jakob disease. Brain 126 (2003), 1333–1346.
76. Hodges, J.R., Patterson, K., Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol. 6 (2007), 1004–1014.
77. Isacson, O., Seo, H., Lin, L., Albeck, D., Granholm, A.C., Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci. 25 (2002), 79–84.
78. Jack, C.R. Jr., PART and SNAP. Acta Neuropathol. 128 (2014), 773–776.
79. Jack, C.R. Jr., Holtzman, D.M., Biomarker modeling of Alzheimer's disease. Neuron 80 (2013), 1347–1358.
80. Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., Shaw, L.M., Vemuri, P., Wiste, H.J., Weigand, S.D., Lesnick, T.G., Pankratz, V.S., Donohue, M.C., Trojanowski, J.Q., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12 (2013), 207–216.
81. Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9 (2010), 119–128.
82. Jack, C.R. Jr., Knopman, D.S., Weigand, S.D., Wiste, H.J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J.L., Senjem, M.L., Ivnik, R.J., Roberts, R.O., Rocca, W.A., Boeve, B.F., Petersen, R.C., An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 71 (2012), 765–775.
83. Jack, C.R. Jr., Lowe, V.J., Senjem, M.L., Weigand, S.D., Kemp, B.J., Shiung, M.M., Knopman, D.S., Boeve, B.F., Klunk, W.E., Mathis, C.A., Petersen, R.C., 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131 (2008), 665–680.
84. Jack, C.R. Jr., Lowe, V.J., Weigand, S.D., Wiste, H.J., Senjem, M.L., Knopman, D.S., Shiung, M.M., Gunter, J.L., Boeve, B.F., Kemp, B.J., Weiner, M., Petersen, R.C., Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132 (2009), 1355–1365.
85. Jack, C.R. Jr., Weigand, S.D., Shiung, M.M., Przybelski, S.A., O'Brien, P.C., Gunter, J.L., Knopman, D.S., Boeve, B.F., Smith, G.E., Petersen, R.C., Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 70 (2008), 1740–1752.
86. Jack, C.R. Jr., Wiste, H.J., Lesnick, T.G., Weigand, S.D., Knopman, D.S., Vemuri, P., Pankratz, V.S., Senjem, M.L., Gunter, J.L., Mielke, M.M., Lowe, V.J., Boeve, B.F., Petersen, R.C., Brain beta-amyloid load approaches a plateau. Neurology 80 (2013), 890–896.
87. Jack, C.R. Jr., Wiste, H.J., Weigand, S.D., Knopman, D.S., Lowe, V., Vemuri, P., Mielke, M.M., Jones, D.T., Senjem, M.L., Gunter, J.L., Gregg, B.E., Pankratz, V.S., Petersen, R.C., Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 81 (2013), 1732–1740.
88. Jagust, W., Reed, B., Mungas, D., Ellis, W., Decarli, C., What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 69 (2007), 871–877.
89. Jagust, W.J., Landau, S.M., Alzheimer's Disease Neuroimaging Initiative, Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J. Neurosci. 32 (2012), 18227–18233.
90. Jansen, W.J., Ossenkoppele, R., Knol, D.L., Tijms, B.M., Scheltens, P., Verhey, F.R., Visser, P.J., Amyloid Biomarker Study, G., Aalten, P., Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I.S., Arnold, S.E., Baldeiras, I., Barthel, H., van Berckel, B.N., Bibeau, K., Blennow, K., Brooks, D.J., van Buchem, M.A., Camus, V., Cavedo, E., Chen, K., Chetelat, G., Cohen, A.D., Drzezga, A., Engelborghs, S., Fagan, A.M., Fladby, T., Fleisher, A.S., van der Flier, W.M., Ford, L., Forster, S., Fortea, J., Foskett, N., Frederiksen, K.S., Freund-Levi, Y., Frisoni, G.B., Froelich, L., Gabryelewicz, T., Gill, K.D., Gkatzima, O., Gomez-Tortosa, E., Gordon, M.F., Grimmer, T., Hampel, H., Hausner, L., Hellwig, S., Herukka, S.K., Hildebrandt, H., Ishihara, L., Ivanoiu, A., Jagust, W.J., Johannsen, P., Kandimalla, R., Kapaki, E., Klimkowicz-Mrowiec, A., Klunk, W.E., Kohler, S., Koglin, N., Kornhuber, J., Kramberger, M.G., Van Laere, K., Landau, S.M., Lee, D.Y., de Leon, M., Lisetti, V., Lleo, A., Madsen, K., Maier, W., Marcusson, J., Mattsson, N., de Mendonca, A., Meulenbroek, O., Meyer, P.T., Mintun, M.A., Mok, V., Molinuevo, J.L., Mollergard, H.M., Morris, J.C., Mroczko, B., Van der Mussele, S., Na, D.L., Newberg, A., Nordberg, A., Nordlund, A., Novak, G.P., Paraskevas, G.P., Parnetti, L., Perera, G., Peters, O., Popp, J., Prabhakar, S., Rabinovici, G.D., Ramakers, I.H., Rami, L., Resende de Oliveira, C., Rinne, J.O., Rodrigue, K.M., Rodriguez-Rodriguez, E., Roe, C.M., Rot, U., Rowe, C.C., Ruther, E., Sabri, O., Sanchez-Juan, P., Santana, I., Sarazin, M., Schroder, J., Schutte, C., Seo, S.W., Soetewey, F., Soininen, H., Spiru, L., Struyfs, H., Teunissen, C.E., Tsolaki, M., Vandenberghe, R., Verbeek, M.M., Villemagne, V.L., Vos, S.J., van Waalwijk van Doorn, L.J., Waldemar, G., Wallin, A., Wallin, A.K., Wiltfang, J., Wolk, D.A., Zboch, M., Zetterberg, H., Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313 (2015), 1924–1938.
91. Jellinger, K., Morphology of Alzheimer disease and related disorders. Maurer, K., Riederer, P., Beckmann, H., (eds.) Alzheimer Disease: Epidemiology, Neuropathology, Neurochemistry, and Clinics, 1990, Springer-Verlag, Berlin, 61–77.
92. Jellinger, K.A., Con: can neuropathology really confirm the exact diagnosis?. Alzheimers Res. Ther., 2, 2010, 11.
93. Jellinger, K.A., Attems, J., Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J. Neurol. Sci. 229–230 (2005), 37–41.
94. Jellinger, K.A., Bancher, C., Neuropathology of Alzheimer's disease: a critical update. J. Neural Transm. Suppl. 54 (1998), 77–95.
95. Johnson, K.A., Gregas, M., Becker, J.A., Kinnecom, C., Salat, D.H., Moran, E.K., Smith, E.E., Rosand, J., Rentz, D.M., Klunk, W.E., Mathis, C.A., Price, J.C., Dekosky, S.T., Fischman, A.J., Greenberg, S.M., Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol. 62 (2007), 229–234.
96. Johnson, K.A., Schultz, A., Betensky, R.A., Becker, J.A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., Marshall, G., Albers, M., Mauro, S., Pepin, L., Alverio, J., Judge, K., Philiossaint, M., Shoup, T., Yokell, D., Dickerson, B., Gomez-Isla, T., Hyman, B., Vasdev, N., Sperling, R., Tau PET imaging in aging and early Alzheimer's disease. Ann. Neurol., 2015, 10.1002/ana.24546.
97. Johnson, N., Davis, T., Bosanquet, N., The epidemic of Alzheimer's disease. How can we manage the costs?. Pharmacoeconomics 18 (2000), 215–223.
98. Josephs, K.A., Holton, J.L., Rossor, M.N., Godbolt, A.K., Ozawa, T., Strand, K., Khan, N., Al-Sarraj, S., Revesz, T., Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol. Appl. Neurobiol. 30 (2004), 369–373.
99. Kantarci, K., Lowe, V., Przybelski, S.A., Weigand, S.D., Senjem, M.L., Ivnik, R.J., Preboske, G.M., Roberts, R., Geda, Y.E., Boeve, B.F., Knopman, D.S., Petersen, R.C., Jack, C.R. Jr., APOE modifies the association between Abeta load and cognition in cognitively normal older adults. Neurology 78 (2012), 232–240.
100. Kemppainen, N.M., Aalto, S., Wilson, I.A., Nagren, K., Helin, S., Bruck, A., Oikonen, V., Kailajarvi, M., Scheinin, M., Viitanen, M., Parkkola, R., Rinne, J.O., PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68 (2007), 1603–1606.
101. Kennedy, A.M., Frackowiak, R.S., Newman, S.K., Bloomfield, P., Seaward, J., Roques, P., Lewington, G., Cunningham, V.J., Rossor, M.N., Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett. 186 (1995), 17–20.
102. Khachaturian, Z.S., Diagnosis of Alzheimer's disease. Arch. Neurol. 42 (1985), 1097–1105.
103. Klunk, W.E., Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol. Aging 32:Suppl. 1 (2011), S20–36.
104. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergstrom, M., Savitcheva, I., Huang, G.F., Estrada, S., Ausen, B., Debnath, M.L., Barletta, J., Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A., Langstrom, B., Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 55 (2004), 306–319.
105. Klunk, W.E., Price, J.C., Mathis, C.A., Tsopelas, N.D., Lopresti, B.J., Ziolko, S.K., Bi, W., Hoge, J.A., Cohen, A.D., Ikonomovic, M.D., Saxton, J.A., Snitz, B.E., Pollen, D.A., Moonis, M., Lippa, C.F., Swearer, J.M., Johnson, K.A., Rentz, D.M., Fischman, A.J., Aizenstein, H.J., DeKosky, S.T., Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 27 (2007), 6174–6184.
106. Knopman, D.S., Alzheimer disease biomarkers and insights into mild cognitive impairment. Neurology 80 (2013), 978–980.
107. Knopman, D.S., Jack, C.R. Jr., Wiste, H.J., Weigand, S.D., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J.L., Senjem, M.L., Ivnik, R.J., Roberts, R.O., Boeve, B.F., Petersen, R.C., Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78 (2012), 1576–1582.
108. Knudsen, K.A., Rosand, J., Karluk, D., Greenberg, S.M., Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 56 (2001), 537–539.
109. Koivunen, J., Pirttila, T., Kemppainen, N., Aalto, S., Herukka, S.K., Jauhianen, A.M., Hanninen, T., Hallikainen, M., Nagren, K., Rinne, J.O., Soininen, H., PET amyloid ligand [C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 26 (2008), 378–383.
110. Koivunen, J., Verkkoniemi, A., Aalto, S., Paetau, A., Ahonen, J.P., Viitanen, M., Nagren, K., Rokka, J., Haaparanta, M., Kalimo, H., Rinne, J.O., PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 131 (2008), 1845–1853.
111. Kudo, Y., Okamura, N., Furumoto, S., Tashiro, M., Furukawa, K., Maruyama, M., Itoh, M., Iwata, R., Yanai, K., Arai, H., 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy) benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med. 48 (2007), 553–561.
112. La Joie, R., Perrotin, A., Barre, L., Hommet, C., Mezenge, F., Ibazizene, M., Camus, V., Abbas, A., Landeau, B., Guilloteau, D., de La Sayette, V., Eustache, F., Desgranges, B., Chetelat, G., Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia. J. Neurosci. 32 (2012), 16265–16273.
113. Landau, S.M., Harvey, D., Madison, C.M., Koeppe, R.A., Reiman, E.M., Foster, N.L., Weiner, M.W., Jagust, W.J., Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 32:7 (2009), 1207–1218.
114. Larson, E.B., Edwards, J.K., O'Meara, E., Nochlin, D., Sumi, S.M., Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia. J. Gerontol. A: Biol. Sci. Med. Sci. 51:suppl. 6 (1996), M313–M318.
115. Leyton, C.E., Villemagne, V.L., Savage, S., Pike, K.E., Ballard, K.J., Piguet, O., Burrell, J.R., Rowe, C.C., Hodges, J.R., Subtypes of progressive aphasia: application of the international consensus criteria and validation using {beta}-amyloid imaging. Brain 134:Pt 10 (2011), 3030–3043.
116. Liberski, P.P., Amyloid plaques in transmissible spongiform encephalopathies (prion diseases). Folia Neuropathol. 42:Suppl. B (2004), 109–119.
117. Lowe, V.J., Kemp, B.J., Jack, C.R. Jr., Senjem, M., Weigand, S., Shiung, M., Smith, G., Knopman, D., Boeve, B., Mullan, B., Petersen, R.C., Comparison of 18F-FDG and PiB PET in cognitive impairment. J. Nucl. Med. 50 (2009), 878–886.
118. Mackenzie, I.R., Foti, D., Woulfe, J., Hurwitz, T.A., Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131 (2008), 1282–1293.
119. Maetzler, W., Liepelt, I., Reimold, M., Reischl, G., Solbach, C., Becker, C., Schulte, C., Leyhe, T., Keller, S., Melms, A., Gasser, T., Berg, D., Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol. Dis. 34 (2009), 107–112.
120. Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., Mucke, L., Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 12245–12250.
121. Masters, C.L., Neuropathology of Alzheimer's disease. Burns, A., O'Brien, J., Ames, D., (eds.) Dementia, 3rd ed., 2005, Hodder Arnold, London, 393–407.
122. Masters, C.L., Beyreuther, K., The neuropathology of Alzheimer's disease in the year 2005. Beal, M.F., Lang, A.E., Ludolph, A.C., (eds.) Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics, 2005, Cambridge University Press, Cambridge, 433–440.
123. Masters, C.L., Beyreuther, K., Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 129 (2006), 2823–2839.
124. Masters, C.L., Cappai, R., Barnham, K.J., Villemagne, V.L., Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J. Neurochem. 97 (2006), 1700–1725.
125. Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., Beyreuther, K., Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 82 (1985), 4245–4249.
126. Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S.D., Bernardini, S., Bocchio-Chiavetto, L., Blankenstein, M.A., Carrillo, M.C., Chalbot, S., Coart, E., Chiasserini, D., Cutler, N., Dahlfors, G., Duller, S., Fagan, A.M., Forlenza, O., Frisoni, G.B., Galasko, D., Galimberti, D., Hampel, H., Handberg, A., Heneka, M.T., Herskovits, A.Z., Herukka, S.K., Holtzman, D.M., Humpel, C., Hyman, B.T., Iqbal, K., Jucker, M., Kaeser, S.A., Kaiser, E., Kapaki, E., Kidd, D., Klivenyi, P., Knudsen, C.S., Kummer, M.P., Lui, J., Llado, A., Lewczuk, P., Li, Q.X., Martins, R., Masters, C., McAuliffe, J., Mercken, M., Moghekar, A., Molinuevo, J.L., Montine, T.J., Nowatzke, W., O'Brien, R., Otto, M., Paraskevas, G.P., Parnetti, L., Petersen, R.C., Prvulovic, D., de Reus, H.P., Rissman, R.A., Scarpini, E., Stefani, A., Soininen, H., Schroder, J., Shaw, L.M., Skinningsrud, A., Skrogstad, B., Spreer, A., Talib, L., Teunissen, C., Trojanowski, J.Q., Tumani, H., Umek, R.M., Van Broeck, B., Vanderstichele, H., Vecsei, L., Verbeek, M.M., Windisch, M., Zhang, J., Zetterberg, H., Blennow, K., The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7 (2011), 386–395 e386.
127. Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., Herukka, S.K., van der Flier, W.M., Blankenstein, M.A., Ewers, M., Rich, K., Kaiser, E., Verbeek, M., Tsolaki, M., Mulugeta, E., Rosen, E., Aarsland, D., Visser, P.J., Schroder, J., Marcusson, J., de Leon, M., Hampel, H., Scheltens, P., Pirttila, T., Wallin, A., Jonhagen, M.E., Minthon, L., Winblad, B., Blennow, K., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302 (2009), 385–393.
128. Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C., Yarasheski, K.E., Bateman, R.J., Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science, 330, 2010, 1774.
129. McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., Cummings, J., Duda, J.E., Lippa, C., Perry, E.K., Aarsland, D., Arai, H., Ballard, C.G., Boeve, B., Burn, D.J., Costa, D., Del Ser, T., Dubois, B., Galasko, D., Gauthier, S., Goetz, C.G., Gomez-Tortosa, E., Halliday, G., Hansen, L.A., Hardy, J., Iwatsubo, T., Kalaria, R.N., Kaufer, D., Kenny, R.A., Korczyn, A., Kosaka, K., Lee, V.M., Lees, A., Litvan, I., Londos, E., Lopez, O.L., Minoshima, S., Mizuno, Y., Molina, J.A., Mukaetova-Ladinska, E.B., Pasquier, F., Perry, R.H., Schulz, J.B., Trojanowski, J.Q., Yamada, M., Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005), 1863–1872.
130. McKeith, I.G., Mosimann, U.P., Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat. Disord. 10:Suppl. 1 (2004), S15–18.
131. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R. Jr., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S., Phelps, C.H., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7 (2011), 263–269.
132. Michaelis, M.L., Dobrowsky, R.T., Li, G., Tau neurofibrillary pathology and microtubule stability. J. Mol. Neurosci. 19 (2002), 289–293.
133. Mintun, M.A., Larossa, G.N., Sheline, Y.I., Dence, C.S., Lee, S.Y., Mach, R.H., Klunk, W.E., Mathis, C.A., DeKosky, S.T., Morris, J.C., [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67 (2006), 446–452.
134. Mormino, E.C., Kluth, J.T., Madison, C.M., Rabinovici, G.D., Baker, S.L., Miller, B.L., Koeppe, R.A., Mathis, C.A., Weiner, M.W., Jagust, W.J., Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132 (2009), 1310–1323.
135. Morris, J.C., Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch. Neurol., 2012, 10.1001/archneurol.2011.3152.
136. Morris, J.C., Kimberly, A., Quaid, K., Holtzman, D.M., Kantarci, K., Kaye, J., Reiman, E.M., Klunk, W.E., Siemers, E.R., Role of biomarkers in studies of presymptomatic Alzheimer's disease. Alzheimers Dement. 1 (2005), 145–151.
137. Morris, J.C., Price, A.L., Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci. 17 (2001), 101–118.
138. Morris, J.C., Roe, C.M., Grant, E.A., Head, D., Storandt, M., Goate, A.M., Fagan, A.M., Holtzman, D.M., Mintun, M.A., Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66 (2009), 1469–1475.
139. Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff, V., Salmon, E., Baron, J.C., De Cristofaro, M.T., Padovani, A., Borroni, B., Franceschi, M., Bracco, L., Pupi, A., MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63 (2004), 2332–2340.
140. Mosconi, L., De Santi, S., Li, Y., Li, J., Zhan, J., Tsui, W.H., Boppana, M., Pupi, A., de Leon, M.J., Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur. J. Nucl. Med. Mol. Imaging 33 (2006), 210–221.
141. Mosconi, L., Sorbi, S., de Leon, M.J., Li, Y., Nacmias, B., Myoung, P.S., Tsui, W., Ginestroni, A., Bessi, V., Fayyazz, M., Caffarra, P., Pupi, A., Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J. Nucl. Med. 47 (2006), 1778–1786.
142. Mott, R.T., Dickson, D.W., Trojanowski, J.Q., Zhukareva, V., Lee, V.M., Forman, M., Van Deerlin, V., Ervin, J.F., Wang, D.S., Schmechel, D.E., Hulette, C.M., Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J. Neuropathol. Exp. Neurol. 64 (2005), 420–428.
143. Neumann, M., Rademakers, R., Roeber, S., Baker, M., Kretzschmar, H.A., Mackenzie, I.R., A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132 (2009), 2922–2931.
144. Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M., McCluskey, L.F., Miller, B.L., Masliah, E., Mackenzie, I.R., Feldman, H., Feiden, W., Kretzschmar, H.A., Trojanowski, J.Q., Lee, V.M., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 (2006), 130–133.
145. O'Brien, J., Ames, D., Burns, A., Dementia. 2nd ed., 2000, Arnold, London.
146. Okamura, N., Shiga, Y., Furumoto, S., Tashiro, M., Tsuboi, Y., Furukawa, K., Yanai, K., Iwata, R., Arai, H., Kudo, Y., Itoyama, Y., Doh-ura, K., In vivo detection of prion amyloid plaques using [(11)C]BF-227 PET. Eur. J. Nucl. Med. Mol. Imaging 37 (2010), 934–941.
147. Okello, A., Edison, P., Archer, H.A., Turkheimer, F.E., Kennedy, J., Bullock, R., Walker, Z., Kennedy, A., Fox, N., Rossor, M., Brooks, D.J., Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 72 (2009), 56–62.
148. Okello, A., Koivunen, J., Edison, P., Archer, H.A., Turkheimer, F.E., Nagren, K., Bullock, R., Walker, Z., Kennedy, A., Fox, N.C., Rossor, M.N., Rinne, J.O., Brooks, D.J., Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73 (2009), 754–760.
149. Ong, K., Villemagne, V.L., Bahar-Fuchs, A., Lamb, F., Chetelat, G., Raniga, P., Mulligan, R.S., Salvado, O., Putz, B., Roth, K., Masters, C.L., Reininger, C.B., Rowe, C.C., (18)F-florbetaben Abeta imaging in mild cognitive impairment. Alzheimers Res. Ther., 5, 2013, 4.
150. Ong, K.T., Villemagne, V.L., Bahar-Fuchs, A., Lamb, F., Langdon, N., Catafau, A.M., Stephens, A.W., Seibyl, J., Dinkelborg, L.M., Reininger, C.B., Putz, B., Rohde, B., Masters, C.L., Rowe, C.C., Abeta imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. J. Neurol. Neurosurg. Psychiatry 86 (2015), 431–436.
151. Ostrowitzki, S., Deptula, D., Thurfjell, L., Barkhof, F., Bohrmann, B., Brooks, D.J., Klunk, W.E., Ashford, E., Yoo, K., Xu, Z.X., Loetscher, H., Santarelli, L., Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 69:2 (2011), 198–207.
152. Petersen, R.C., Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 15 (2000), 93–101.
153. Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., Kokmen, E., Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56 (1999), 303–308.
154. Pettersen, J.A., Sathiyamoorthy, G., Gao, F.Q., Szilagyi, G., Nadkarni, N.K., St George-Hyslop, P., Rogaeva, E., Black, S.E., Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch. Neurol. 65 (2008), 790–795.
155. Pike, K.E., Ellis, K.A., Villemagne, V.L., Good, N., Chetelat, G., Ames, D., Szoeke, C., Laws, S.M., Verdile, G., Martins, R.N., Masters, C.L., Rowe, C.C., Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 49 (2011), 2384–2390.
156. Pike, K.E., Savage, G., Villemagne, V.L., Ng, S., Moss, S.A., Maruff, P., Mathis, C.A., Klunk, W.E., Masters, C.L., Rowe, C.C., Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130 (2007), 2837–2844.
157. Pimplikar, S.W., Nixon, R.A., Robakis, N.K., Shen, J., Tsai, L.H., Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J. Neurosci. 30 (2010), 14946–14954.
158. Pletnikova, O., West, N., Lee, M.K., Rudow, G.L., Skolasky, R.L., Dawson, T.M., Marsh, L., Troncoso, J.C., Abeta deposition is associated with enhanced cortical a-synuclein lesions in Lewy body diseases. Neurobiol. Aging, 26, 2005.
159. Price, J.C., Klunk, W.E., Lopresti, B.J., Lu, X., Hoge, J.A., Ziolko, S.K., Holt, D.P., Meltzer, C.C., DeKosky, S.T., Mathis, C.A., Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J. Cereb. Blood Flow Metab. 25 (2005), 1528–1547.
160. Rabinovici, G.D., Furst, A.J., O'Neil, J.P., Racine, C.A., Mormino, E.C., Baker, S.L., Chetty, S., Patel, P., Pagliaro, T.A., Klunk, W.E., Mathis, C.A., Rosen, H.J., Miller, B.L., Jagust, W.J., 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68 (2007), 1205–1212.
161. Rabinovici, G.D., Jagust, W.J., Furst, A.J., Ogar, J.M., Racine, C.A., Mormino, E.C., O'Neil, J.P., Lal, R.A., Dronkers, N.F., Miller, B.L., Gorno-Tempini, M.L., Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann. Neurol. 64 (2008), 388–401.
162. Rabinovici, G.D., Miller, B.L., Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 24 (2010), 375–398.
163. Rabinovici, G.D., Rosen, H.J., Alkalay, A., Kornak, J., Furst, A.J., Agarwal, N., Mormino, E.C., O'Neil, J.P., Janabi, M., Karydas, A., Growdon, M.E., Jang, J.Y., Huang, E.J., Dearmond, S.J., Trojanowski, J.Q., Grinberg, L.T., Gorno-Tempini, M.L., Seeley, W.W., Miller, B.L., Jagust, W.J., Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 77 (2011), 2034–2042.
164. Reiman, E.M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S.A., Langbaum, J.B., Alexander, G.E., Klunk, W.E., Mathis, C.A., Price, J.C., Aizenstein, H.J., DeKosky, S.T., Caselli, R.J., Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 6820–6825.
165. Reiman, E.M., Quiroz, Y.T., Fleisher, A.S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A.M., Shah, A.R., Alvarez, S., Arbelaez, A., Giraldo, M., Acosta-Baena, N., Sperling, R.A., Dickerson, B., Stern, C.E., Tirado, V., Munoz, C., Reiman, R.A., Huentelman, M.J., Alexander, G.E., Langbaum, J.B., Kosik, K.S., Tariot, P.N., Lopera, F., Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 11 (2012), 1048–1056.
166. Rentz, D.M., Locascio, J.J., Becker, J.A., Moran, E.K., Eng, E., Buckner, R.L., Sperling, R.A., Johnson, K.A., Cognition, reserve, and amyloid deposition in normal aging. Ann. Neurol. 67 (2010), 353–364.
167. Resende, R., Pereira, C., Agostinho, P., Vieira, A.P., Malva, J.O., Oliveira, C.R., Susceptibility of hippocampal neurons to Abeta peptide toxicity is associated with perturbation of Ca2+ homeostasis. Brain Res. 1143 (2007), 11–21.
168. Resnick, S.M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D.P., Dannals, R.F., Mathis, C.A., Klunk, W.E., Ferrucci, L., Kraut, M.A., Wong, D.F., Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 74 (2010), 807–815.
169. Rinne, J.O., Brooks, D.J., Rossor, M.N., Fox, N.C., Bullock, R., Klunk, W.E., Mathis, C.A., Blennow, K., Barakos, J., Okello, A.A., Rodriguez Martinez de Liano, S., Liu, E., Koller, M., Gregg, K.M., Schenk, D., Black, R., Grundman, M., 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9 (2010), 363–372.
170. Roder, S., Danober, L., Pozza, M.F., Lingenhoehl, K., Wiederhold, K.H., Olpe, H.R., Electrophysiological studies on the hippocampus and prefrontal cortex assessing the effects of amyloidosis in amyloid precursor protein 23 transgenic mice. Neuroscience 120 (2003), 705–720.
171. Roe, C.M., Mintun, M.A., D'Angelo, G., Xiong, C., Grant, E.A., Morris, J.C., Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh compound B uptake. Arch. Neurol. 65 (2008), 1467–1471.
172. Rossor, M.N., Kennedy, A.M., Frackowiak, R.S., Clinical and neuroimaging features of familial Alzheimer's disease. Ann. N. Y. Acad. Sci. 777 (1996), 49–56.
173. Rowe, C.C., Bourgeat, P., Ellis, K.A., Brown, B., Lim, Y.Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., Robins, P., Tochon-Danguy, H., O'Keefe, G., Pike, K.E., Yates, P., Szoeke, C., Salvado, O., Macaulay, S.L., O'Meara, T., Head, R., Cobiac, L., Savage, G., Martins, R., Masters, C.L., Ames, D., Villemagne, V.L., Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann. Neurol. 74 (2013), 905–913.
174. Rowe, C.C., Ellis, K.A., Rimajova, M., Bourgeat, P., Pike, K.E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., Price, R., Raniga, P., Robins, P., Acosta, O., Lenzo, N., Szoeke, C., Salvado, O., Head, R., Martins, R., Masters, C.L., Ames, D., Villemagne, V.L., Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31 (2010), 1275–1283.
175. Rowe, C.C., Ng, S., Ackermann, U., Gong, S.J., Pike, K., Savage, G., Cowie, T.F., Dickinson, K.L., Maruff, P., Darby, D., Smith, C., Woodward, M., Merory, J., Tochon-Danguy, H., O'Keefe, G., Klunk, W.E., Mathis, C.A., Price, J.C., Masters, C.L., Villemagne, V.L., Imaging beta-amyloid burden in aging and dementia. Neurology 68 (2007), 1718–1725.
176. Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L.S., Porsteinsson, A.P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I.C., Liu, E.C., Grundman, M., Yuen, E., Black, R., Brashear, H.R., Clinical, B., Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370 (2014), 322–333.
177. Salmon, E., Sadzot, B., Maquet, P., Degueldre, C., Lemaire, C., Rigo, P., Comar, D., Franck, G., Differential diagnosis of Alzheimer's disease with PET. J. Nucl. Med. 35 (1994), 391–398.
178. Scheltens, P., Dementia: Mild cognitive impairment—amyloid and beyond. Nat. Rev. Neurol. 9 (2013), 493–495.
179. Scheltens, P., Rockwood, K., How golden is the gold standard of neuropathology in dementia?. Alzheimers Dement. 7 (2011), 486–489.
180. Schulz-Schaeffer, W.J., The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 120 (2010), 131–143.
181. Shaw, L.M., Korecka, M., Clark, C.M., Lee, V.M., Trojanowski, J.Q., Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discov. 6 (2007), 295–303.
182. Sheline, Y.I., Morris, J.C., Snyder, A.Z., Price, J.L., Yan, Z., D'Angelo, G., Liu, C., Dixit, S., Benzinger, T., Fagan, A., Goate, A., Mintun, M.A., APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. J. Neurosci. 30 (2010), 17035–17040.
183. Silverman, D.H., Cummings, J.L., Small, G.W., Gambhir, S.S., Chen, W., Czernin, J., Phelps, M.E., Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol. Imaging Biol. 4 (2002), 283–293.
184. Silverman, D.H., Small, G.W., Chang, C.Y., Lu, C.S., Kung De Aburto, M.A., Chen, W., Czernin, J., Rapoport, S.I., Pietrini, P., Alexander, G.E., Schapiro, M.B., Jagust, W.J., Hoffman, J.M., Welsh-Bohmer, K.A., Alavi, A., Clark, C.M., Salmon, E., de Leon, M.J., Mielke, R., Cummings, J.L., Kowell, A.P., Gambhir, S.S., Hoh, C.K., Phelps, M.E., Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286 (2001), 2120–2127.
185. Small, G.W., Mazziotta, J.C., Collins, M.T., Baxter, L.R., Phelps, M.E., Mandelkern, M.A., Kaplan, A., La Rue, A., Adamson, C.F., Chang, L., et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273 (1995), 942–947.
186. Small, S.A., Duff, K., Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60 (2008), 534–542.
187. Snowden, J., Neary, D., Mann, D., Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol. 114 (2007), 31–38.
188. Sojkova, J., Resnick, S.M., In vivo human amyloid imaging. Curr. Alzheimer Res. 8 (2011), 366–372.
189. Sojkova, J., Zhou, Y., An, Y., Kraut, M.A., Ferrucci, L., Wong, D.F., Resnick, S.M., Longitudinal patterns of beta-amyloid deposition in nondemented older adults. Arch. Neurol. 68 (2011), 644–649.
190. Sperling, R., Johnson, K., Pro: can biomarkers be gold standards in Alzheimer's disease?. Alzheimers Res. Ther., 2, 2010, 17.
191. Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., Iwatsubo, T., Jack, C.R. Jr., Kaye, J., Montine, T.J., Park, D.C., Reiman, E.M., Rowe, C.C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M.C., Thies, B., Morrison-Bogorad, M., Wagster, M.V., Phelps, C.H., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7 (2011), 280–292.
192. Sperling, R.A., Jack, C.R. Jr., Aisen, P.S., Testing the right target and right drug at the right stage. Sci. Transl. Med. 3 (2011), 111–133.
193. Sperling, R.A., Jack, C.R. Jr., Black, S.E., Frosch, M.P., Greenberg, S.M., Hyman, B.T., Scheltens, P., Carrillo, M.C., Thies, W., Bednar, M.M., Black, R.S., Brashear, H.R., Grundman, M., Siemers, E.R., Feldman, H.H., Schindler, R.J., Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 7 (2011), 367–385.
194. Sperling, R.A., Johnson, K.A., Doraiswamy, P.M., Reiman, E.M., Fleisher, A.S., Sabbagh, M.N., Sadowsky, C.H., Carpenter, A., Davis, M.D., Lu, M., Flitter, M., Joshi, A.D., Clark, C.M., Grundman, M., Mintun, M.A., Skovronsky, D.M., Pontecorvo, M.J., Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol. Aging 34:3 (2012), 822–831.
195. Sperling, R.A., Laviolette, P.S., O'Keefe, K., O'Brien, J., Rentz, D.M., Pihlajamaki, M., Marshall, G., Hyman, B.T., Selkoe, D.J., Hedden, T., Buckner, R.L., Becker, J.A., Johnson, K.A., Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63 (2009), 178–188.
196. Storandt, M., Head, D., Fagan, A.M., Holtzman, D.M., Morris, J.C., Toward a multifactorial model of Alzheimer disease. Neurobiol. Aging 33:10 (2012), 2262–2271.
197. Storandt, M., Mintun, M.A., Head, D., Morris, J.C., Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch. Neurol. 66 (2009), 1476–1481.
198. Strozyk, D., Blennow, K., White, L.R., Launer, L.J., CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60 (2003), 652–656.
199. Sunderland, T., Gur, R.E., Arnold, S.E., The use of biomarkers in the elderly: current and future challenges. Biol. Psychiatry 58 (2005), 272–276.
200. Taniguchi, S., McDonagh, A.M., Pickering-Brown, S.M., Umeda, Y., Iwatsubo, T., Hasegawa, M., Mann, D.M., The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein. Neuropathol. Appl. Neurobiol. 30 (2004), 1–18.
201. Teipel, S., Drzezga, A., Grothe, M.J., Barthel, H., Chetelat, G., Schuff, N., Skudlarski, P., Cavedo, E., Frisoni, G.B., Hoffmann, W., Thyrian, J.R., Fox, C., Minoshima, S., Sabri, O., Fellgiebel, A., Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. Lancet Neurol. 14 (2015), 1037–1053.
202. Thal, L.J., Kantarci, K., Reiman, E.M., Klunk, W.E., Weiner, M.W., Zetterberg, H., Galasko, D., Pratico, D., Griffin, S., Schenk, D., Siemers, E., The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20 (2006), 6–15.
203. Tolboom, N., van der Flier, W.M., Yaqub, M., Boellaard, R., Verwey, N.A., Blankenstein, M.A., Windhorst, A.D., Scheltens, P., Lammertsma, A.A., van Berckel, B.N., Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J. Nucl. Med. 50 (2009), 1464–1470.
204. Toledo, J.B., Bjerke, M., Da, X., Landau, S.M., Foster, N.L., Jagust, W., Jack, C. Jr., Weiner, M., Davatzikos, C., Shaw, L.M., Trojanowski, J.Q., Alzheimer's Disease Neuroimaging Initiative Investigators, I., Nonlinear association between cerebrospinal fluid and florbetapir F-18 beta-amyloid measures across the spectrum of Alzheimer disease. JAMA Neurol. 72 (2015), 571–581.
205. Toledo, J.B., Xie, S.X., Trojanowski, J.Q., Shaw, L.M., Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI. Acta Neuropathol. 126 (2013), 659–670.
206. Venneti, S., Lopresti, B.J., Wiley, C.A., The peripheral benzodiazepine receptor (Translocator protein 18 kDa) in microglia: from pathology to imaging. Prog. Neurobiol. 80 (2006), 308–322.
207. Vernooij, M.W., van der Lugt, A., Ikram, M.A., Wielopolski, P.A., Niessen, W.J., Hofman, A., Krestin, G.P., Breteler, M.M., Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 70 (2008), 1208–1214.
208. Villain, N., Chetelat, G., Grassiot, B., Bourgeat, P., Jones, G., Ellis, K.A., Ames, D., Martins, R.N., Eustache, F., Salvado, O., Masters, C.L., Rowe, C.C., Villemagne, V.L., Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 135 (2012), 2126–2139.
209. Villemagne, V.L., Ataka, S., Mizuno, T., Brooks, W.S., Wada, Y., Kondo, M., Jones, G., Watanabe, Y., Mulligan, R., Nakagawa, M., Miki, T., Shimada, H., O'Keefe, G.J., Masters, C.L., Mori, H., Rowe, C.C., High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch. Neurol. 66 (2009), 1537–1544.
210. Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., Szoeke, C., Macaulay, S.L., Martins, R., Maruff, P., Ames, D., Rowe, C.C., Masters, C.L., Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12 (2013), 357–367.
211. Villemagne, V.L., Cappai, R., Barnham, K.J., Cherny, R., Opazo, C., Novakovic, K.E., Rowe, C.C., Masters, C.L., The Aβ centric pathway of Alzheimer's disease. Barrow, C.J., Small, B.J., (eds.) Abeta Peptide and Alzheimer's Disease, 2006, Springer-Verlag, London, 5–32.
212. Villemagne, V.L., Fodero-Tavoletti, M.T., Pike, K.E., Cappai, R., Masters, C.L., Rowe, C.C., The ART of loss: Aβ imaging in the evaluation of Alzheimer's disease and other dementias. Mol. Neurobiol. 38 (2008), 1–15.
213. Villemagne, V.L., Furumoto, S., Fodero-Tavoletti, M.T., Mulligan, R.S., Hodges, J., Harada, R., Yates, P., Piguet, O., Pejoska, S., Dore, V., Yanai, K., Masters, C.L., Kudo, Y., Rowe, C.C., Okamura, N., In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 41 (2014), 816–826.
214. Villemagne, V.L., Furumoto, S., Fodero-Tavoletti, M.T., Mulligan, R.S., Hodges, J., Piguet, O., Pejoska, S., Kudo, Y., Masters, C.L., Yanai, K., Rowe, C.C., Okamura, N., In vivo tau imaging in Alzheimer's disease and other dementias. Alzheimer Dement., 8, 2012, P9.
215. Villemagne, V.L., McLean, C.A., Reardon, K., Boyd, A., Lewis, V., Klug, G., Jones, G., Baxendale, D., Masters, C.L., Rowe, C.C., Collins, S.J., 11C-PiB PET studies in typical sporadic Creutzfeldt–Jakob disease. J. Neurol. Neurosurg. Psychiatry 80 (2009), 998–1001.
216. Villemagne, V.L., Ong, K., Mulligan, R.S., Holl, G., Pejoska, S., Jones, G., O'Keefe, G., Ackerman, U., Tochon-Danguy, H., Chan, J.G., Reininger, C.B., Fels, L., Putz, B., Rohde, B., Masters, C.L., Rowe, C.C., Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J. Nucl. Med. 52 (2011), 1210–1217.
217. Villemagne, V.L., Pike, K.E., Chetelat, G., Ellis, K.A., Mulligan, R.S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., Martins, R., O'Keefe, G., Mathis, C.A., Klunk, W.E., Ames, D., Masters, C.L., Rowe, C.C., Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann. Neurol. 69 (2011), 181–192.
218. Villemagne, V.L., Pike, K.E., Darby, D., Maruff, P., Savage, G., Ng, S., Ackermann, U., Cowie, T.F., Currie, J., Chan, S.G., Jones, G., Tochon-Danguy, H., O'Keefe, G., Masters, C.L., Rowe, C.C., Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46 (2008), 1688–1697.
219. Villemagne, V.L., Rowe, C.C., Amyloid ligands for dementia. PET Clin. 5 (2010), 33–53.
220. Villeneuve, S., Reed, B.R., Wirth, M., Haase, C.M., Madison, C.M., Ayakta, N., Mack, W., Mungas, D., Chui, H.C., DeCarli, C., Weiner, M.W., Jagust, W.J., Cortical thickness mediates the effect of beta-amyloid on episodic memory. Neurology 82 (2014), 761–767.
221. Vishnu, V.Y., Can tauopathy shake the amyloid cascade hypothesis?. Nat. Rev. Neurol., 9, 2013, 356.
222. Vlassenko, A.G., Mintun, M.A., Xiong, C., Sheline, Y.I., Goate, A.M., Benzinger, T.L., Morris, J.C., Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann. Neurol. 70 (2011), 857–861.
223. Wahlund, L.O., Blennow, K., Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci. Lett. 339 (2003), 99–102.
224. Weiner, M.W., Dementia in 2012: further insights into Alzheimer disease pathogenesis. Nat. Rev. Neurol. 9 (2013), 65–66.
225. Weller, R.O., Preston, S.D., Subash, M., Carare, R.O., Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res. Ther., 1, 2009, 6.
226. Wermke, M., Sorg, C., Wohlschlager, A.M., Drzezga, A., A new integrative model of cerebral activation, deactivation and default mode function in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 35:Suppl. 1 (2008), S12–24.
227. Wiley, C.A., Lopresti, B.J., Venneti, S., Price, J., Klunk, W.E., DeKosky, S.T., Mathis, C.A., Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch. Neurol. 66 (2009), 60–67.
228. Wirth, M., Villeneuve, S., Haase, C.M., Madison, C.M., Oh, H., Landau, S.M., Rabinovici, G.D., Jagust, W.J., Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 70 (2013), 1512–1519.
229. Wolk, D.A., Price, J.C., Saxton, J.A., Snitz, B.E., James, J.A., Lopez, O.L., Aizenstein, H.J., Cohen, A.D., Weissfeld, L.A., Mathis, C.A., Klunk, W.E., DeKosky, S.T., Amyloid imaging in mild cognitive impairment subtypes. Ann. Neurol. 65 (2009), 557–568.
230. Yates, P.A., Sirisriro, R., Villemagne, V.L., Farquharson, S., Masters, C.L., Rowe, C.C., Cerebral microhemorrhage and brain {beta}-amyloid in aging and Alzheimer disease. Neurology 77 (2011), 48–54.
231. Yokokura, M., Mori, N., Yagi, S., Yoshikawa, E., Kikuchi, M., Yoshihara, Y., Wakuda, T., Sugihara, G., Takebayashi, K., Suda, S., Iwata, Y., Ueki, T., Tsuchiya, K.J., Suzuki, K., Nakamura, K., Ouchi, Y., In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 38 (2011), 343–351.